Supplementary Information

Microglial Clearance of Alzheimer's Amyloid-Beta Obstructed by Nanoplastics

Yue Wang,^{1,2} Gangtong Huang,³ Xiufang Liang,^{1,2} Nicholas Andrikopoulos,^{4,5} Huayuan Tang,⁶ Feng Ding,^{3*} Pu Chun Ke^{7*} and Yuhuan Li^{7,8*}

 ¹ School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou, 510006, China
² Nanomedicine Center, The Great Bay Area National Institute for Nanotechnology Innovation, 136 Kaiyuan Avenue, Guangzhou, 510700, China
³ Department of Physics and Astronomy, Clemson University, Clemson, SC 29634, USA
⁴ Department of Materials Science and Engineering, Monash University, Clayton, VIC 3800, Australia
⁵ ARC Training Centre for Cell and Tissue Engineering Technologies, Monash University, Clayton, VIC 3800, Australia
⁶ Department of Engineering Mechanics, Hohai University, Nanjing 211100, China
⁷ Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia
⁸ Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, 200032, China

Corresponding Authors

Email: Feng Ding, fding@clemson.edu; Pu Chun Ke, pu-chun.ke@monash.edu; Yuhuan Li, li.yuhuan1@zs-hospital.sh.cn

Adsorption of A_β onto nanoplastics

A β (25 μ M) was prepared in phosphate buffered saline (PBS) solution and incubated separately at 37 °C for 1, 3, and 6 h with or without the nanoplastics (0.2 mg/mL). Samples were ultracentrifuged at 12,000 g for 15 min, and the supernatant was collected. A BCA kit (Thermo Fisher, USA) was used to measure A β concentration at 562 nm using a microplate reader (BioTek Synergy H1, USA). For confocal fluorescence imaging, HMC3 cells (8×10⁴ cells/well) were seeded in 35 mm dishes. After 12 h, the cells were treated with FITC-A β (25 μ M) and red fluorescently-labeled PS nanoplastics (0.2 mg/mL) for 24 h. The cells were then washed three times with 1×PBS, fixed in 4% paraformaldehyde solution (Solarbio, China) for 1 h, and rinsed once with 1×PBS for 5 min. Afterwards, the cells were stained with DAPI (4',6-diamidino-2phenylindole, Solarbio, China) at room temperature for 5 min. Images were captured with a confocal fluorescence microscope (Nikon Eclipse Ti2-E, Japan) at a 60× magnification. DAPI: Ex 405 nm/Em 460 nm, PS: Ex 560 nm/Em 620 nm, FITC-A β : Ex 488 nm/Em 525 nm.

Cellular uptake mechanism

HMC3 cells (3×10^{6} cells/well) were seeded in 6-well plates and cultured until attachment. The cells were pre-treated with methyl- β -cyclodextrin (M β CD, 5 mM), 5-(N-Ethyl-N-isopropyl)-Amiloride (EIPA, 30 μ M), or monodansylcadaverine (MDC, 10 μ M) for 2 h. FITC-labeled A β or PS nanoplastics were used to visualize their intracellular uptake. The cells were incubated with FITC-PS (0.2 mg/mL) or FITC-A β (25 μ M) for 3 h. Flow cytometry was used to determine the proportion of positive cells.



Fig. S1 Adsorption capacity of A β to PS nanoplastics. (A) A BCA assay in phosphatebuffered saline (PBS) buffer (n = 3). (B) Representative confocal fluorescence images of HMC3 cells treated with A β (25 µM) and PS nanoplastics (0.2 mg/mL) for 24 h. (C) Single-channel images of Fig. S1B. Green: FITC-labeled A β . Red: Fluorescently-labeled PS nanoplastics. Blue: nucleus. Scale bar: 10 µm. Data are presented as mean ± SD and analyzed using two-tailed Student's t-tests. * P < 0.05, *** P < 0.001 represent significant differences compared with the A β group.



Fig. S2 Secondary structure, energy and dynamics of the simulation systems. (A) Time evolutions of the secondary structure and energy of an A β monomer with a PS nanoplastic and an A β dimer with and without a PS nanoplastic. (B) Residue-wise secondary structure content of A β in the presence of a nanoplastic, averaged across the two chains of the A β dimer. (C) Time evolution of the distance between two A β peptide chains and the PS nanoplastic for all 25 trajectories involving the interactants. The orange and blue colors correspond to the two separate A β peptide chains, respectively.



Fig. S3 A β promoted microglial uptake of PS nanoplastics. (A) Intracellular fluorescence of A β and PS nanoplastics in HMC3 cells determined by flow cytometry. (B, C) Histograms from panel A showing cellular uptake of the nanoplastics (B) or A β (C). (D) Overlay of the histograms in panel C. (E) Statistical analysis of intracellular fluorescence intensity of A β (n = 3). Data are presented as mean ± SD and were analyzed using one-way ANOVA, followed by Tukey's posthoc tests. *** *P* < 0.001 represents significant differences compared with control, # *P* < 0.05 represents significant differences between treatment groups, and n.s. represents no significant difference.



Fig. S4 M β CD (5 mM) and EIPA (30 μ M) inhibited microglial uptake of PS nanoplastics. Cells were pre-treated with different endocytosis inhibitors (5 mM M β CD, 30 μ M EIPA, 10 μ M MDC) for 2 h. The cells were then treated with FITC-labeled PS nanoplastics (0.2 mg/mL) for 3 h. A flow cytometer was used to determine the proportion of FITC-PS positive cells (n = 3).



Fig. S5 EIPA (30 μ M) inhibited microglial uptake of A β . HMC3 cells were pre-treated with different endocytosis inhibitors (5 mM M β CD, 30 μ M EIPA, 10 μ M MDC) for 2 h. Then the cells were exposed to FITC-labeled A β (25 μ M) for 3 h. A flow cytometer was used to determine the proportion of FITC-PS-positive cells (n = 3).



Fig. S6 Split bright field or fluorescence images of Fig. 3C. Scale bar: 100 µm.



Fig. S7 KEGG pathway enrichment analysis from all detected proteins. The horizontal axis represents the number of proteins in the KEGG annotation entries and the vertical axis displays the enriched terms.



Fig. S8 Raw images of western blot bands in Fig. 3D.



Fig. S9 Western blot assays (A) and quantifications of DGKA (B) and APOE4 (H) expressions. Data are shown as mean \pm SD and were analyzed using one-way ANOVA, followed by Tukey's post-hoc tests (n = 3). * P < 0.05, ** P < 0.01, *** P < 0.001 represent significant differences compared with the control, and #P < 0.05, #P < 0.01 represent significant differences between treatment groups.

DGKA (~80 KDa)				
Lares: 1 2 3 4 5 6 7 8 9 10 11 ~180 KDa ~130 KDa ~100 KDa ~70 KDa ~55 KDa	12 13 14 15	Lane 1: Marker Lane 2: Control Lane 3: PS Lane 4: Aβ Lane 5: Aβ + PS	Lane 6: Marker Lane 7: Control Lane 8: PS Lane 9: Aβ Lane10: Aβ + PS	Lane 11: Marker Lane 12: Control Lane 13: PS Lane 14: Aβ Lane 15: Aβ + PS
APOE4 (~35 KDa)				
Lanes; 1 2 3 4 5 ~35 KDa ~ 25 KDa	Lane 1: Marker Lane 2: Control Lane 3: PS Lane 4: Aβ Lane 5: Aβ + PS			
Lanes: 1 2, 3, 4 5 ~35 KDa ~25 KDa	Lane 1: Marker Lane 2: Control Lane 3: PS Lane 4: Aβ Lane 5: Aβ + PS			
Lanes: 1 2 3 4 5 ~35 KDa ~25 KDa	Lane 1: Marker Lane 2: Control Lane 3: PS Lane 4: Aβ Lane 5: Aβ + PS			
GAPDH (~37 KDa)				
Lanes: 1 2 3 4 5 ~40 KDa Lane 1: Mark ~35 KDa Lane 2: Com ~25 KDa Lane 4: Aβ ~15 KDa Lane 5: Aβ + 400	ker trol - PS			
Lanes: 1 2 3 4 5 6 7 8 ~40 KDa ~35 KDa ~25 KDa	9 10 L	ane 1: Marker ane 2: Control ane 3: PS ane 4: Aβ ane 5: Aβ + PS	Lane 6: Marker Lane 7: Control Lane 8: PS Lane 9: Aβ Lane10: Aβ + PS	

Fig. S10 Raw images of western blot bands in Fig. S9.

Gene	Primer sequences	
INOS	F: AGAAACCTGCTCTACGAACTGT	
	R: GGGAAGCGAGTCTTTCAGAAG	
TNF	F: CCTCTCTCTAATCAGCCCTCTG	
	R: GAGGACCTGGGAGTAGATGAG	
IL-10	F: TCAAGGCGCATGTGAACTCC	
	R: GATGTCAAACTCACTCATGGCT	
Arg-1	F: TGGACAGACTAGGAATTGGCA	
	R: CCAGTCCGTCAACATCAAAACT	
GAPDH	F: ACAACTTTGGTATCGTGGAAGG	
	R: GCCATCACGCCACAGTTTC	

Table S1. Primer sequences applied in RT-qPCR.

_ I able S2. Antibodies used in the study.		
Antibodies	Product origin	
Anti-Iba1/AIF-1	Cell Signaling Technology	
Anti-DGKA	Abcam	
Anti-Apolipoprotein E4	Abcam	
Anti-GAPDH	Abcam	
IgG-HRP	Absin	

Table S2. Antibodies used in the study.